Gabapentin Capsule
Product Images NDC 71335-1997

7 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-1997). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin-formula-jpg.jpg (Gabapentin Formula Jpg)

Gabapentin-formula-jpg.jpg (Gabapentin Formula Jpg)
A pharmacokinetic formula calculating creatinine clearance (CLCr) based on age, weight, serum creatinine, and a correction factor for female patients, used in drug dosing considerations for gabapentin.*
FDA Label Image

Gaba-structure.jpg (Gaba Structure)

Gaba-structure.jpg (Gaba Structure)
Chemical structure of gabapentin, illustrating its molecular framework with a cyclohexane ring and attached amino and carboxymethyl groups.*
FDA Label Image

Gaba-fig-1-jpg.jpg (Gaba Fig 1 Jpg)

Gaba-fig-1-jpg.jpg (Gaba Fig 1 Jpg)
A line graph showing mean pain scores over 8 weeks comparing placebo and gabapentin at 3600 mg/day. The x-axis is labeled Weeks from Baseline to 8, and the y-axis is labeled Mean Pain Score from 0 to 10. The graph includes markers for a 4-week dose titration period followed by a 4-week fixed dose period. Gabapentin shows a decreasing pain score trend, while placebo remains relatively stable.*
FDA Label Image

Gaba-fig-2-jpg.jpg (Gaba Fig 2 Jpg)

Gaba-fig-2-jpg.jpg (Gaba Fig 2 Jpg)
A line graph showing mean pain scores over a 7-week study period with two phases: a 3-week dose titration and a 4-week fixed dose. It compares placebo and two doses of Gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks, and the y-axis represents mean pain scores from 0 to 10.*
FDA Label Image

Gaba-fig-3-jpg.jpg (Gaba Fig 3 Jpg)

Gaba-fig-3-jpg.jpg (Gaba Fig 3 Jpg)
A bar graph titled 'Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' showing responder percentages in two studies. Study 1 compares placebo (12%) to Gabapentin 3600 mg (29%), and Study 2 compares placebo (14%) to Gabapentin 1800 mg (32%) and 2400 mg (34%). Statistical significance is indicated for Gabapentin doses versus placebo with p-values less than 0.01 and 0.001.*
FDA Label Image

Gaba-fig-4-jpg.jpg (Gaba Fig 4 Jpg)

Gaba-fig-4-jpg.jpg (Gaba Fig 4 Jpg)
A scatter plot comparing percentage difference by daily dose in milligrams for three studies labeled a, b, and c. The x-axis represents daily doses from 600 mg to 1800 mg, and the y-axis shows percentage difference from 2% to 22%. Data points for study a are shown in black, study b in gray, and study c in white with distinct percentage differences at given doses.*
FDA Label Image

Label (Lbl713351997)

Label (Lbl713351997)
Gabapentin Capsules, USP 300 mg oral capsules label by Bryant Ranch Prepack. The label includes the NDC 71335-1997-01, states the package contains 30 capsules, and has storage instructions for controlled room temperature. Also shown is the BRP Pharmaceuticals logo and a note indicating 'Rx only.'*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.